

Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction and Structural Remodelling in a Rat Model of Chronic Kidney Disease

Supplementary Figures

Omar Z. Ameer^a, Mark Butlin^a, Elena Kaschina^b, Manuela Sommerfeld^b, Alberto P. Avolio^a,
and Jacqueline K. Phillips^{a*}

^a *Department of Biomedical Science, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.*


^b *Center for Cardiovascular Research and Institute of Pharmacology, Charité - Universitätsmedizin, Berlin, Germany.*

* Correspondence: jacqueline.phillips@mq.edu.au

Supplementary Figures


Supplementary Figure 1: MMP9

Immunohistochemical staining for matrix metalloproteinase 9 (MMP9) in the aortic wall of Lewis (A, B) and Lewis polycystic kidney (LPK; C, D) rats. Images are from untreated (A, C) and treated animals (valsartan; panels B, D). Media cysts are evident in the vessel wall (arrows). MMP9 expression was evident in the adventitia, in the media (*) and in association with cysts. When assessed as % area of media staining, there was a significant strain effect ($P<0.001$) with MMP9 staining greater in the LPK compared to Lewis (Lewis: 2.7 ± 1.3 vs. LPK 6.2 ± 2.3 % area, $P<0.001$, $n=15$ & 11 animals, respectively). There was also a significant treatment*strain interaction ($P=0.033$) which was due to a decrease in MMP9 staining in the LPK group after valsartan treatment, such that it was no longer significantly different to the Lewis valsartan treated group ($p=0.158$). Panel E: $*P<0.05$ between LPK and Lewis groups as indicated.



Supplementary Figure 2: Cathepsin D

Immunohistochemical staining for Cathepsin D in the aortic wall of Lewis (A, B) and Lewis polycystic kidney (LPK; C, D) rats. Images are from untreated (A, C) and treated animals (valsartan; panels B, D). Cathepsin D expression was also evident in the adventitia, in the media (*) and in association with cysts (arrows). When assessed as % area of media staining, there was a significant strain effect, being greater overall in the LPK (Lewis 2.8 ± 1.9 % area vs. LPK: 6.3 ± 3.9 ; $P=0.027$, $n=13$ & 11 animals, respectively). There was no significant treatment effect or treatment*strain interaction. Panel E: $*P<0.05$ between LPK and Lewis groups as indicated.



Supplementary Figure 3: Nuclear Factor Kappa B

Immunohistochemical staining for nuclear factor kappa B (NFκB) in the aortic wall of Lewis (A, B) and Lewis polycystic kidney (LPK; C, D) rats. Images are from untreated (A, C) and treated animals (valsartan; panels B, D). NFκB staining was found in the cell deposits on the intima, colocalizing with the inflammatory cells on the endothelium (*) and was also present in the adventitia in both strains. Expression was noted around cysts in the vessel wall (arrows). There was a significant difference between Lewis and LPK when assessed as % area of the media immunoreactive for NFκB (Lewis $2.3 \pm 1.4\%$ area vs. LPK: 6.7 ± 2.9 , $n = 13$ & 10 animals respectively $P < 0.001$). There was a trend towards a significant treatment*strain interaction but this was not significant ($P = 0.064$). Panel E: * $P < 0.05$ between LPK and Lewis groups as indicated.

